Orchestra BioMed Holdings, Inc.

NasdaqGM OBIO

Orchestra BioMed Holdings, Inc. Current Liabilities for the quarter ending September 30, 2024: USD 16.22 M

Orchestra BioMed Holdings, Inc. Current Liabilities is USD 16.22 M for the quarter ending September 30, 2024, a -24.47% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.
  • Orchestra BioMed Holdings, Inc. Current Liabilities for the quarter ending September 30, 2023 was USD 21.47 M.
Key data
Date Current Liabilities Total Non-Current Liabilities Shareholders' Equity Long-Term Debt
Market news
SV Wall Street
NasdaqGM: OBIO

Orchestra BioMed Holdings, Inc.

CEO Mr. David P. Hochman
IPO Date Aug. 4, 2020
Location United States
Headquarters 150 Union Square Drive
Employees 56
Sector Healthcare
Industries
Biotechnology 3D Printing Clinical Trials Fintech Medical Instruments Pharmaceuticals Robotics Telehealth
Description

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

StockViz Staff

February 11, 2025

Any question? Send us an email